Laboratoires Thea is the lead sponsor of 5 current clinical trials in our USA, UK, India and EU (CTIS) registers. 2 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Sepofarsen. The most-studied condition is Leber Congenital Amaurosis 10.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
NCT07169695 · ClinicalTrials.gov ↗ · Moderate to Severe Vernal Keratoconjunctivitis
|
Phase 2 | Recruiting | 2026-03 | India |
|
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT06891443 · ClinicalTrials.gov ↗ · Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis
Drug: Sepofarsen |
Phase 3 | Recruiting | 2025-06 | UK, USA |
|
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
NCT05389267 · Glaucoma, Ocular Hypertension
|
Phase 1/2 | Active, closed | 2022-07 | USA |
|
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179 · ClinicalTrials.gov ↗ · Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind
|
Phase 2 | Active, closed | 2024-12 | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Laboratoires Thea as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)
2025-521567-12-00 · CTIS ↗ · Eye Diseases
|
Phase 2 | Authorised | Spain, Italy, Bulgaria + 2 more |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 1 |
| Clinical trials in UK | 2 | 1 |
| Clinical trials in India | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
Laboratoires Thea is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA, UK and India registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Sepofarsen (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.